Tu Xu, Ph.D.
Affiliations: | 2013 | Mathematics, Statistics, and Computer Science | University of Illinois at Chicago, Chicago, IL, United States |
Area:
Biostatistics, EpidemiologyGoogle:
"Tu Xu"Parents
Sign in to add mentorSamad Hedayat | grad student | 2013 | University of Illinois, Chicago | |
(New Developments Of Minimum Clinically Important Difference: Theory and Methodology.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Wei AH, Strickland SA, Hou JZ, et al. (2019) Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801600 |
DiNardo CD, Pratz K, Pullarkat V, et al. (2018) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood |
Lee JS, Roberts A, Juarez D, et al. (2018) Statins enhance efficacy of venetoclax in blood cancers. Science Translational Medicine. 10 |
DiNardo CD, Pratz KW, Letai A, et al. (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. The Lancet. Oncology |
Wei A, Strickland SA, Hou J, et al. (2018) Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy Blood. 132: 284-284 |
Pollyea DA, Pratz KW, Jonas BA, et al. (2018) Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy Blood. 132: 285-285 |
DiNardo CD, Pratz K, Potluri J, et al. (2018) Durable Response with Venetoclax in Combination with Decitabine or Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Clinical Lymphoma Myeloma and Leukemia. 18: S201 |
Kumar S, Kaufman JL, Gasparetto C, et al. (2017) Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood |
Bueno O, Xu T, Cordero J, et al. (2017) Phase 2, open-label study of venetoclax in combination with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 35: TPS8056-TPS8056 |
Potluri J, Xu T, Hong W, et al. (2017) Phase 3, randomized, double-blind, placebo-controlled study of venetoclax combined with azacitidine versus azacitidine in treatment-naïve patients with acute myeloid leukemia. Journal of Clinical Oncology. 35 |